MVP 3.37% 43.0¢ medical developments international limited

Share price has doubled, no announcements, page-76

  1. 822 Posts.
    lightbulb Created with Sketch. 9
    Did a quick maths to see current situation. Based on the below, you are looking at EV to revenue multiple of less than 2 with revenue still growing at a healthy 30%. I'm guessing a net cash position of $30m at the end of June. That should be plenty for next couple of years presuming they won't invest their own money to complete Phase 3 trial and await a partner or other funding opportunities. This would allow them to generate NPAT by the time Phase 3 really kicks in.

    This doesn't take into consideration recent $1.5 grant and any tax breaks. No matter which way you look it, the company looks incredibly cheap. I think the drag on the share price is because there is literally zero interest at the moment and these opportunities such as USA has been spoken about for a long time since 2018 and we still have not been through trials 4 years later. To be totally fair, 2 of those 4 years have been lost to COVID and USA regulatory matters do take time. They just need to be done and over with and the upside is potentially asymmetric.

    DYO research.


    https://hotcopper.com.au/data/attachments/5495/5495400-49be4daa371674ba3382aef514edf440.jpg
 
watchlist Created with Sketch. Add MVP (ASX) to my watchlist
(20min delay)
Last
43.0¢
Change
-0.015(3.37%)
Mkt cap ! $48.44M
Open High Low Value Volume
44.5¢ 44.5¢ 41.5¢ $118.8K 278.4K

Buyers (Bids)

No. Vol. Price($)
1 1192 43.0¢
 

Sellers (Offers)

Price($) Vol. No.
44.0¢ 5000 1
View Market Depth
Last trade - 16.10pm 18/11/2024 (20 minute delay) ?
MVP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.